Estrogen and progestin hormonal receptors: Do they have a developmental role in males with Papillary thyroid cancer?
PDF (Español (España))


Thyroid cancer

How to Cite

Duque, C. S., Vélez, A., Isaza, A., Londoño, A., Dueñas, J. P. ., Zuleta, J. J., & Agudelo, M. (2022). Estrogen and progestin hormonal receptors: Do they have a developmental role in males with Papillary thyroid cancer?. Revista Colombiana De Endocrinología, Diabetes &Amp; Metabolismo, 8(4).


Context: Thyroid cancer is more common in women than in men, in this regard a theory has been proposed explaining the origin of this tumor due to the female hormones, to date this hypothesis has not been proven yet.
Objective: A pilot study was proposed to examine the possibility of finding female hormonal markers in tissue from male patients who were operated due to thyroid cancer.
Methodology: Tissues samples from ten male patients with thyroid cancer were subjected to immunohistochemical techniques with markers for estrogen and progesterone.
Results: None of the tissue samples from this patients subjected to immunohistochemical studies in this pilot study reacted to the female hormonal markers.
Conclusions: This pilot study of a small case series did not demonstrate a hormonal
relationship in thyroid tissue from males with papillary cancer to estrogen or progestogen markers.
PDF (Español (España))


Lechner M. G., Praws S. S., Angell T. E. Treatment of differentiated thyroid carcinomas. Surg Pathol Clin 2019, 12(4):931-42.

La Vecchia C., Malvezzi M., Bosetti C., Garavelo W., Bertuccio P., Levi F., et al. Thyroid cancer mortality and incidence: a global overview. Int J Cancer 2015,136(9):2187-95.

Yildirim Simsir I., Cetinkalb S., Kabalak T. Review of factors contributing to nodular goiter and thyroid carcinoma. Med Princ Pract 2019 29(1):1-5.

Bresciani L., Orlandi E., Piazza C. Radiation-induced papillary thyroid cancer: is it a distinct clinical entity? Curr Opin Otolaryngol. Head Neck Surg 2019, 27(2): 117-22.

Zane M., Parello C., Pennelli G., Townsend D. M., Merigliano S., Boscaro M., et al. Estrogen and thyroid cancer is a stem affair: A preliminary study. Biomed Pharmacother 2017, 85: 399-411.

Rahbar R., Zhang L., Kebebew E. Thyroid cancer gender disparity. Future Oncol, 2010; 6(11), 1771-79.

Braganza M. Z., de González A. B., Schonfeld S. J., Wentzensen N., Brenner A. V., Kitahara, C. M. Benign breast and gynecologic conditions, reproductive and hormonal factors, and risk of thyroid cancer. Can Prev Res (Phila). 2014; 7(4), 418-25.

Zivaljevic V., Slijepcevic N., Sipetic S., Paunovic I., Diklic A., Zoric, et al. Risk factors for well-differentiated thyroid cancer in men. Tumori 2013; 99(4), 458-62.

Schonfeld S. J., Neta G., Sturgis E. M., Pfeiffer R. M., Hutchinson A. A., Xu L. et al. Common genetic variants I sex hormone pathways genes and papillary thyroid cancer risk. Thyroid 2012, 22(2):151-156.

Wang P., Ly L., Qi F., Qiu F. Increased risk of papillary thyroid cancer related to hormonal factors in women. Tumour Biol 2015, 36(7):5127-32.

Moleti M., Sturniolo G., Di Mauro M., Russo M., Vermiglio F. Female reproductive factors and differentiated thyroid cancer. Front Endocrinol (Lausanne) 2017, 23(8) 111.

Choi M. H., Moon J.-Y., Choo S.-H., Chul B., Eun C., Lee E.J. Metabolic alteration of urinary steroids in pre- and post-menopausal women, and men with papillary thyroid carcinoma. BMC Cancer 2011, 8(11) 342.

Manole D., Schildknecht B., Gosnell B., Adamas E., Derwahl M. Estrogen promotes growth of human thyroid tumor cells by different molecular mechanisms. J Clin Endocrinol Metab. 2001, 83(3):1072-7.

Chan E., Sepkovic D. W., Bowne H. J., Yu G. P., Schantz S. P. A hormonal association between estrogen metabolism and proliferative thyroid disease. Otolaryngol Head Neck Surg. 2006, 134(6): 893-900.

. Derwahl M., Nicula D. Estrogen and its role in thyroid cancer. Endocr Relat Cancer. 2014 Oct;21(5): T273-83.

Rubio G. A., Catanuto P., Glassberg M. K., Lew J. I., Elliot S. J. Estrogen receptor subtype expression and regulation is altered in papillary thyroid cancer after menopause. Surgery. 2018 Jan;163(1):143-149.

Santin A. P., Furlanetto T. W. Role of estrogen in thyroid function and growth regulation.. Thyroid Res. 2011; 2011: 875125.

Wang F., Zhao S., Shen X., Zhu G., Liu R., Viola D. et al. (2018). BRAF V600E confers male sex disease-specific mortality risk in patients with papillary thyroid cancer. J Clin Oncol 2018 20; 36(27), 2787-95.

Suzuki H., Willingham M. C., Cheng S. Y. Mice with a mutation in the thyroid hormone receptor ? gene spontaneously develop thyroid carcinoma: a mouse model of thyroid carcinogenesis. Thyroid, 2002 12(11), 963-9.

Zhang Y., Liu L., Liu Y., Cao N., Wang L., Xing C. Clinical significance of immunohistochemistry to detect BRAF V600E mutant protein in thyroid tissues. Medicine (Baltimore). 2021 Apr 23;100(16): e25566. PMID: 33879712.

Liu H., Lin F. Application of immunohistochemistry in thyroid pathology. Arch Pathol Lab Med. 2015 Jan;139(1):67-82. PMID: 25549145.

Ahmed R. A., Aboelnaga E. M. Thyroid cancer in Egypt: histopathological, correlation with survival and estrogen receptor protein expression. Pathol Oncol Res. 2014,21, (3): 793-802..

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Copyright (c) 2021 Revista Endocrino




Download data is not yet available.